Non-executive director Guo Huaqing increased his holdings of SciClone Pharmaceuticals (02171) by 30,000 shares at a price of HK$14.98 per share.
On December 15th, non-executive director Guo Huaqing increased his holdings in Keji Pharmaceutical (02171) by 30,000 shares, at a price of HK$14.98 per share, with a total amount of HK$449,400.
The latest data from the Hong Kong Stock Exchange shows that on December 15th, non-executive director Guo Huaqing increased his holdings of Keji Medicine (02171) by 30,000 shares, with a price of 14.98 Hong Kong dollars per share, for a total amount of 449,400 Hong Kong dollars. After the increase, the latest number of shares held is approximately 224 million, with a shareholding ratio of 38.75%.
Related Articles
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Hims & Hers Health (HIMS.US) launches cheap weight loss pills, FDA stops sales the next day, stock price plummets after hours.
HK Bull/Bear Outstanding Qty Ratio(76:24) | February 7th
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Hims & Hers Health (HIMS.US) launches cheap weight loss pills, FDA stops sales the next day, stock price plummets after hours.
HK Bull/Bear Outstanding Qty Ratio(76:24) | February 7th
